Header Logo

Connection

RITSUKO KOMAKI to Aged

Back to Details
This is a "connection" page, showing publications RITSUKO KOMAKI has written about Aged.
RITSUKO KOMAKI
Connection Strength
1.466
Aged
  1. Is prophylactic cranial irradiation indicated for patients with extensive-stage small cell lung cancer with a complete response to first-line treatment? Radiother Oncol. 2018 06; 127(3):339-343.
    View in: PubMed
    Score: 0.025
  2. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018 Mar; 126(3):499-505.
    View in: PubMed
    Score: 0.025
  3. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer. Am J Clin Oncol. 2017 Dec; 40(6):625-630.
    View in: PubMed
    Score: 0.024
  4. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol. 2017 11; 12(11):1696-1703.
    View in: PubMed
    Score: 0.024
  5. Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: Do all patients benefit? Radiother Oncol. 2017 02; 122(2):307-312.
    View in: PubMed
    Score: 0.023
  6. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382.
    View in: PubMed
    Score: 0.023
  7. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
    View in: PubMed
    Score: 0.021
  8. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 2014 Jul; 112(1):30-6.
    View in: PubMed
    Score: 0.019
  9. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1082-9.
    View in: PubMed
    Score: 0.017
  10. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e531-6.
    View in: PubMed
    Score: 0.017
  11. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol. 2012 Mar 15; 7:33.
    View in: PubMed
    Score: 0.016
  12. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011 Jun 10; 29(17):2312-8.
    View in: PubMed
    Score: 0.015
  13. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy. J Radiat Res. 2010; 51(4):465-71.
    View in: PubMed
    Score: 0.015
  14. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer. 2009 Jul 15; 115(14):3233-42.
    View in: PubMed
    Score: 0.014
  15. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):802-8.
    View in: PubMed
    Score: 0.014
  16. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol. 2009 Feb; 4(2):179-84.
    View in: PubMed
    Score: 0.013
  17. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol. 2008 Mar; 3(3):277-82.
    View in: PubMed
    Score: 0.012
  18. Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation. Cancer. 2008 Feb 01; 112(3):589-95.
    View in: PubMed
    Score: 0.012
  19. Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. Int J Radiat Oncol Biol Phys. 2007 Jun 01; 68(2):562-71.
    View in: PubMed
    Score: 0.012
  20. Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1030-5.
    View in: PubMed
    Score: 0.012
  21. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1036-46.
    View in: PubMed
    Score: 0.012
  22. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):94-102.
    View in: PubMed
    Score: 0.012
  23. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1399-407.
    View in: PubMed
    Score: 0.011
  24. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol. 2006 Sep 14; 12(34):5501-8.
    View in: PubMed
    Score: 0.011
  25. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):100-7.
    View in: PubMed
    Score: 0.011
  26. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9.
    View in: PubMed
    Score: 0.011
  27. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8.
    View in: PubMed
    Score: 0.010
  28. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64.
    View in: PubMed
    Score: 0.010
  29. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93.
    View in: PubMed
    Score: 0.010
  30. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36.
    View in: PubMed
    Score: 0.010
  31. Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538. JAMA Netw Open. 2024 Oct 01; 7(10):e2440673.
    View in: PubMed
    Score: 0.010
  32. Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2024 Aug 01; 10(8):1111-1115.
    View in: PubMed
    Score: 0.010
  33. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.
    View in: PubMed
    Score: 0.009
  34. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1317-22.
    View in: PubMed
    Score: 0.009
  35. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):114-20.
    View in: PubMed
    Score: 0.009
  36. Outcomes and patterns of failure in bronchial carcinoid tumors. Int J Radiat Oncol Biol Phys. 2003 Jan 01; 55(1):125-31.
    View in: PubMed
    Score: 0.009
  37. Oncodiagnosis panel: 1999. Cancer of the lung: oncodiagnosis. Radiographics. 2001 Nov-Dec; 21(6):1573-96.
    View in: PubMed
    Score: 0.008
  38. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9.
    View in: PubMed
    Score: 0.007
  39. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer. 2021 05; 22(3):225-233.e7.
    View in: PubMed
    Score: 0.007
  40. Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. Am J Clin Oncol. 2020 04; 43(4):231-235.
    View in: PubMed
    Score: 0.007
  41. Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation. JAMA Netw Open. 2020 04 01; 3(4):e201929.
    View in: PubMed
    Score: 0.007
  42. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
    View in: PubMed
    Score: 0.007
  43. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
    View in: PubMed
    Score: 0.007
  44. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. 2019 06 01; 5(6):872-878.
    View in: PubMed
    Score: 0.007
  45. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019 04 01; 103(5):1077-1084.
    View in: PubMed
    Score: 0.007
  46. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer. Clin Lung Cancer. 2019 03; 20(2):117-123.
    View in: PubMed
    Score: 0.007
  47. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. 2019 02 01; 125(3):382-390.
    View in: PubMed
    Score: 0.006
  48. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. Clin Lung Cancer. 2018 11; 19(6):e885-e891.
    View in: PubMed
    Score: 0.006
  49. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295.
    View in: PubMed
    Score: 0.006
  50. Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. JAMA Oncol. 2018 08 01; 4(8):e174504.
    View in: PubMed
    Score: 0.006
  51. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol. 2018 09; 128(3):505-512.
    View in: PubMed
    Score: 0.006
  52. Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. Cancer Med. 2018 06; 7(6):2247-2255.
    View in: PubMed
    Score: 0.006
  53. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology. 2018; 94(6):345-353.
    View in: PubMed
    Score: 0.006
  54. Clinical and Dosimetric Factors Predicting Grade =2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):919-926.
    View in: PubMed
    Score: 0.006
  55. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res. 2018 06; 27(6):1563-1570.
    View in: PubMed
    Score: 0.006
  56. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):558-563.
    View in: PubMed
    Score: 0.006
  57. Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol. 2018 05; 13(5):660-675.
    View in: PubMed
    Score: 0.006
  58. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 02; 13(1):99-106.
    View in: PubMed
    Score: 0.006
  59. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822.
    View in: PubMed
    Score: 0.006
  60. Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis. Am J Clin Oncol. 2018 Jan; 41(1):46-52.
    View in: PubMed
    Score: 0.006
  61. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160.
    View in: PubMed
    Score: 0.006
  62. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer. 2018 02 06; 118(3):331-337.
    View in: PubMed
    Score: 0.006
  63. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737.
    View in: PubMed
    Score: 0.006
  64. Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):452-461.
    View in: PubMed
    Score: 0.006
  65. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Radiother Oncol. 2017 10; 125(1):48-54.
    View in: PubMed
    Score: 0.006
  66. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.006
  67. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.006
  68. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):58-65.
    View in: PubMed
    Score: 0.006
  69. Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5948-5958.
    View in: PubMed
    Score: 0.006
  70. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017 08; 124(2):318-324.
    View in: PubMed
    Score: 0.006
  71. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676.
    View in: PubMed
    Score: 0.006
  72. Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):407-416.
    View in: PubMed
    Score: 0.006
  73. 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med. 2017 11; 58(11):1756-1763.
    View in: PubMed
    Score: 0.006
  74. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol. 2017 06; 123(3):376-381.
    View in: PubMed
    Score: 0.006
  75. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
    View in: PubMed
    Score: 0.006
  76. Long-Term Outcomes of Salvage Stereotactic Ablative?Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. 2017 06; 12(6):983-992.
    View in: PubMed
    Score: 0.006
  77. Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80?Years Old. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):811-819.
    View in: PubMed
    Score: 0.006
  78. A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):820-828.
    View in: PubMed
    Score: 0.006
  79. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017 02; 122(2):274-280.
    View in: PubMed
    Score: 0.006
  80. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):900-907.
    View in: PubMed
    Score: 0.006
  81. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017 Jan; 35(1):56-62.
    View in: PubMed
    Score: 0.006
  82. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
    View in: PubMed
    Score: 0.006
  83. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
    View in: PubMed
    Score: 0.006
  84. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017 May - Jun; 7(3):e195-e203.
    View in: PubMed
    Score: 0.006
  85. Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiother Oncol. 2016 10; 121(1):70-74.
    View in: PubMed
    Score: 0.006
  86. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. Acta Oncol. 2016 Aug; 55(8):1022-8.
    View in: PubMed
    Score: 0.005
  87. Treatment Modalities and Outcomes in Patients With Advanced Invasive Thymoma or Thymic Carcinoma: A Retrospective Multicenter Study. Am J Clin Oncol. 2016 Apr; 39(2):120-5.
    View in: PubMed
    Score: 0.005
  88. MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer. PLoS One. 2016; 11(3):e0150467.
    View in: PubMed
    Score: 0.005
  89. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol. 2016 Mar; 2(3):359-67.
    View in: PubMed
    Score: 0.005
  90. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
    View in: PubMed
    Score: 0.005
  91. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw. 2016 02; 14(2):173-9.
    View in: PubMed
    Score: 0.005
  92. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer. 2016 Mar 15; 122(6):917-28.
    View in: PubMed
    Score: 0.005
  93. Single Nucleotide Polymorphisms in CBLB, a?Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016 07; 17(4):253-262.e5.
    View in: PubMed
    Score: 0.005
  94. Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. Eur Respir J. 2015 Dec; 46(6):1751-61.
    View in: PubMed
    Score: 0.005
  95. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):757-64.
    View in: PubMed
    Score: 0.005
  96. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015 Jun; 115(3):367-72.
    View in: PubMed
    Score: 0.005
  97. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015 Jun; 16(6):630-7.
    View in: PubMed
    Score: 0.005
  98. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 2015 Jul; 17(7):992-8.
    View in: PubMed
    Score: 0.005
  99. Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer. 2015; 15:1095.
    View in: PubMed
    Score: 0.005
  100. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. 2015; 89(2):65-9.
    View in: PubMed
    Score: 0.005
  101. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol. 2015 Mar; 10(3):518-26.
    View in: PubMed
    Score: 0.005
  102. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6.
    View in: PubMed
    Score: 0.005
  103. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb; 16(2):187-99.
    View in: PubMed
    Score: 0.005
  104. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol. 2014 Dec; 113(3):379-84.
    View in: PubMed
    Score: 0.005
  105. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2015 Mar; 16(2):156-63.
    View in: PubMed
    Score: 0.005
  106. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014 Oct; 9(10):1554-60.
    View in: PubMed
    Score: 0.005
  107. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5.
    View in: PubMed
    Score: 0.005
  108. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):819-27.
    View in: PubMed
    Score: 0.005
  109. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol. 2014 Sep; 9(9):1398-405.
    View in: PubMed
    Score: 0.005
  110. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44.
    View in: PubMed
    Score: 0.005
  111. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6.
    View in: PubMed
    Score: 0.005
  112. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1084-1091.
    View in: PubMed
    Score: 0.005
  113. Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Eur J Cancer. 2014 Jul; 50(10):1706-1716.
    View in: PubMed
    Score: 0.005
  114. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1120-8.
    View in: PubMed
    Score: 0.005
  115. Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy. J Thorac Oncol. 2014 Apr; 9(4):534-40.
    View in: PubMed
    Score: 0.005
  116. Can patient comorbidities be included in clinical performance measures for radiation oncology? J Oncol Pract. 2014 May; 10(3):e175-81.
    View in: PubMed
    Score: 0.005
  117. Failure patterns relative to radiation treatment fields for stage II-IV thymoma. J Thorac Oncol. 2014 Mar; 9(3):403-9.
    View in: PubMed
    Score: 0.005
  118. Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. Radiother Oncol. 2014 Mar; 110(3):493-8.
    View in: PubMed
    Score: 0.005
  119. Prognostic value of positron emission tomography/computed tomography findings in limited-stage small cell lung cancer before chemoradiation therapy. Am J Clin Oncol. 2014 Feb; 37(1):77-80.
    View in: PubMed
    Score: 0.005
  120. Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):319-25.
    View in: PubMed
    Score: 0.005
  121. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
    View in: PubMed
    Score: 0.005
  122. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10.
    View in: PubMed
    Score: 0.005
  123. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7.
    View in: PubMed
    Score: 0.005
  124. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013 Oct 20; 31(30):3823-30.
    View in: PubMed
    Score: 0.005
  125. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013 Oct; 109(1):38-44.
    View in: PubMed
    Score: 0.005
  126. Cardiac ?8F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol. 2013 Oct; 109(1):82-8.
    View in: PubMed
    Score: 0.005
  127. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):139-47.
    View in: PubMed
    Score: 0.005
  128. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):885-91.
    View in: PubMed
    Score: 0.005
  129. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9.
    View in: PubMed
    Score: 0.005
  130. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013 Sep 15; 119(18):3402-10.
    View in: PubMed
    Score: 0.004
  131. TGF?1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. PLoS One. 2013; 8(6):e65659.
    View in: PubMed
    Score: 0.004
  132. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69.
    View in: PubMed
    Score: 0.004
  133. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):665-70.
    View in: PubMed
    Score: 0.004
  134. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer. 2013 Jun; 80(3):298-305.
    View in: PubMed
    Score: 0.004
  135. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol. 2013 Mar; 106(3):327-32.
    View in: PubMed
    Score: 0.004
  136. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1312-8.
    View in: PubMed
    Score: 0.004
  137. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45.
    View in: PubMed
    Score: 0.004
  138. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1332-9.
    View in: PubMed
    Score: 0.004
  139. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902.
    View in: PubMed
    Score: 0.004
  140. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim. 2013; 38(4):442-447.
    View in: PubMed
    Score: 0.004
  141. ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1066-73.
    View in: PubMed
    Score: 0.004
  142. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012 Sep 10; 7:152.
    View in: PubMed
    Score: 0.004
  143. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9.
    View in: PubMed
    Score: 0.004
  144. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol. 2012 Aug 28; 7:144.
    View in: PubMed
    Score: 0.004
  145. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1010-6.
    View in: PubMed
    Score: 0.004
  146. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1573-9.
    View in: PubMed
    Score: 0.004
  147. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
    View in: PubMed
    Score: 0.004
  148. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1558-65.
    View in: PubMed
    Score: 0.004
  149. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1017-23.
    View in: PubMed
    Score: 0.004
  150. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1093-100.
    View in: PubMed
    Score: 0.004
  151. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e61-7.
    View in: PubMed
    Score: 0.004
  152. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol. 2012 Apr; 7(4):716-22.
    View in: PubMed
    Score: 0.004
  153. Quantifying the interfractional displacement of the gastroesophageal junction during radiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e273-80.
    View in: PubMed
    Score: 0.004
  154. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e231-9.
    View in: PubMed
    Score: 0.004
  155. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51.
    View in: PubMed
    Score: 0.004
  156. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e537-43.
    View in: PubMed
    Score: 0.004
  157. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e391-8.
    View in: PubMed
    Score: 0.004
  158. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer. J Nucl Med. 2012 Feb; 53(2):225-33.
    View in: PubMed
    Score: 0.004
  159. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):332-9.
    View in: PubMed
    Score: 0.004
  160. TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2011 Oct 14; 11:447.
    View in: PubMed
    Score: 0.004
  161. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012 May 15; 118(10):2632-40.
    View in: PubMed
    Score: 0.004
  162. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 05; 103(19):1452-60.
    View in: PubMed
    Score: 0.004
  163. Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol. 2011 Jul; 6(7):1274-81.
    View in: PubMed
    Score: 0.004
  164. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer. 2012 Jan 15; 118(2):528-35.
    View in: PubMed
    Score: 0.004
  165. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. J Clin Oncol. 2011 Jun 20; 29(18):2590-7.
    View in: PubMed
    Score: 0.004
  166. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1967-72.
    View in: PubMed
    Score: 0.004
  167. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e91-7.
    View in: PubMed
    Score: 0.004
  168. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15; 117(20):4707-13.
    View in: PubMed
    Score: 0.004
  169. Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):e67-73.
    View in: PubMed
    Score: 0.004
  170. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13.
    View in: PubMed
    Score: 0.004
  171. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1350-7.
    View in: PubMed
    Score: 0.004
  172. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):425-34.
    View in: PubMed
    Score: 0.004
  173. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30.
    View in: PubMed
    Score: 0.004
  174. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9.
    View in: PubMed
    Score: 0.004
  175. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):77-84.
    View in: PubMed
    Score: 0.004
  176. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2010 Aug 16; 10:431.
    View in: PubMed
    Score: 0.004
  177. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):91-6.
    View in: PubMed
    Score: 0.004
  178. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010 Jun 16; 102(12):859-65.
    View in: PubMed
    Score: 0.004
  179. The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials. J Thorac Oncol. 2010 May; 5(5):631-9.
    View in: PubMed
    Score: 0.004
  180. The clinical characteristics and non-steroidal treatment for radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. Radiother Oncol. 2010 Oct; 97(1):95-100.
    View in: PubMed
    Score: 0.004
  181. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1387-93.
    View in: PubMed
    Score: 0.004
  182. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
    View in: PubMed
    Score: 0.004
  183. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010 Aug; 24(6):968-74.
    View in: PubMed
    Score: 0.004
  184. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009 Dec 01; 27(34):5816-22.
    View in: PubMed
    Score: 0.003
  185. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009 Jul 01; 115(13):2930-8.
    View in: PubMed
    Score: 0.003
  186. Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8.
    View in: PubMed
    Score: 0.003
  187. Influence of age on choice of therapy and surgical outcomes in patients with nonsmall cell lung cancer. Am Surg. 2009 Jul; 75(7):598-603; discussion 603-4.
    View in: PubMed
    Score: 0.003
  188. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):775-81.
    View in: PubMed
    Score: 0.003
  189. Superior sulcus tumors with vertebral body involvement: a multimodality approach. J Thorac Cardiovasc Surg. 2009 Jun; 137(6):1379-87.
    View in: PubMed
    Score: 0.003
  190. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):412-418.e1-2.
    View in: PubMed
    Score: 0.003
  191. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol. 2009 Jul 10; 27(20):3370-8.
    View in: PubMed
    Score: 0.003
  192. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6.
    View in: PubMed
    Score: 0.003
  193. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):482-9.
    View in: PubMed
    Score: 0.003
  194. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30.
    View in: PubMed
    Score: 0.003
  195. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol. 2009 Jan 30; 4:5.
    View in: PubMed
    Score: 0.003
  196. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res. 2008 Dec 01; 14(23):7832-7.
    View in: PubMed
    Score: 0.003
  197. Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):94-102.
    View in: PubMed
    Score: 0.003
  198. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11.
    View in: PubMed
    Score: 0.003
  199. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol. 2008 Aug; 3(8):858-64.
    View in: PubMed
    Score: 0.003
  200. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008 Oct 01; 26(28):4551-6.
    View in: PubMed
    Score: 0.003
  201. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):119-27.
    View in: PubMed
    Score: 0.003
  202. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):707-14.
    View in: PubMed
    Score: 0.003
  203. A survey of radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy in Japan. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):123-31.
    View in: PubMed
    Score: 0.003
  204. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer. J Thorac Oncol. 2007 Nov; 2(11):1022-8.
    View in: PubMed
    Score: 0.003
  205. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1409-16.
    View in: PubMed
    Score: 0.003
  206. Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction. Radiother Oncol. 2007 Sep; 84(3):283-9.
    View in: PubMed
    Score: 0.003
  207. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):350-7.
    View in: PubMed
    Score: 0.003
  208. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1349-58.
    View in: PubMed
    Score: 0.003
  209. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):389-96.
    View in: PubMed
    Score: 0.003
  210. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 01; 109(1):125-34.
    View in: PubMed
    Score: 0.003
  211. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med. 2006 Nov; 47(11):1756-62.
    View in: PubMed
    Score: 0.003
  212. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer. 2006 Oct 01; 107(7):1467-74.
    View in: PubMed
    Score: 0.003
  213. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol. 2006 Sep 20; 24(27):4485-91.
    View in: PubMed
    Score: 0.003
  214. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74.
    View in: PubMed
    Score: 0.003
  215. Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):108-16.
    View in: PubMed
    Score: 0.003
  216. Surgical patterns of care in operable lung carcinoma treated with radiation. J Thorac Oncol. 2006 Jul; 1(6):526-31.
    View in: PubMed
    Score: 0.003
  217. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006 Jun; 1(5):478-86.
    View in: PubMed
    Score: 0.003
  218. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer. 2006 May 01; 106(9):1998-2004.
    View in: PubMed
    Score: 0.003
  219. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006 Mar 01; 106(5):1017-25.
    View in: PubMed
    Score: 0.003
  220. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72.
    View in: PubMed
    Score: 0.003
  221. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 01; 104(11):2365-72.
    View in: PubMed
    Score: 0.003
  222. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005 Oct 15; 104(8):1620-6.
    View in: PubMed
    Score: 0.003
  223. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005 Oct 01; 104(7):1349-55.
    View in: PubMed
    Score: 0.003
  224. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):667-71.
    View in: PubMed
    Score: 0.003
  225. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. J Clin Oncol. 2005 May 20; 23(15):3480-7.
    View in: PubMed
    Score: 0.003
  226. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20.
    View in: PubMed
    Score: 0.003
  227. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005 May; 79(5):1716-23.
    View in: PubMed
    Score: 0.003
  228. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3342-8.
    View in: PubMed
    Score: 0.003
  229. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8.
    View in: PubMed
    Score: 0.003
  230. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature? Lung Cancer. 2005 Apr; 48(1):93-102.
    View in: PubMed
    Score: 0.003
  231. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol. 2005 Apr 01; 23(10):2145-54.
    View in: PubMed
    Score: 0.003
  232. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005 Mar 15; 11(6):2229-36.
    View in: PubMed
    Score: 0.003
  233. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005 Feb 20; 23(6):1136-43.
    View in: PubMed
    Score: 0.003
  234. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7.
    View in: PubMed
    Score: 0.003
  235. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85.
    View in: PubMed
    Score: 0.002
  236. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
    View in: PubMed
    Score: 0.002
  237. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
    View in: PubMed
    Score: 0.002
  238. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004 Jun; 44(3):369-79.
    View in: PubMed
    Score: 0.002
  239. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54.
    View in: PubMed
    Score: 0.002
  240. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15; 58(4):1258-67.
    View in: PubMed
    Score: 0.002
  241. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 2003 Nov-Dec; 9(6):476-84.
    View in: PubMed
    Score: 0.002
  242. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer. 2003 Oct; 42(1):79-86.
    View in: PubMed
    Score: 0.002
  243. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):120-7.
    View in: PubMed
    Score: 0.002
  244. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2.
    View in: PubMed
    Score: 0.002
  245. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003 Jul 01; 21(13):2529-36.
    View in: PubMed
    Score: 0.002
  246. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21.
    View in: PubMed
    Score: 0.002
  247. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
    View in: PubMed
    Score: 0.002
  248. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003 Jun; 9(6):2085-91.
    View in: PubMed
    Score: 0.002
  249. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):106-13.
    View in: PubMed
    Score: 0.002
  250. Irradiation of para-aortic lymph node metastases from carcinoma of the cervix or endometrium. Preliminary results. Radiology. 1983 Apr; 147(1):245-8.
    View in: PubMed
    Score: 0.002
  251. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003 Mar 01; 55(3):768-75.
    View in: PubMed
    Score: 0.002
  252. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. Clin Cancer Res. 2003 Mar; 9(3):1070-6.
    View in: PubMed
    Score: 0.002
  253. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.002
  254. Long-term follow-up of RTOG 88-05: twice-daily external irradiation with brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2002 Sep 01; 54(1):51-7.
    View in: PubMed
    Score: 0.002
  255. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
    View in: PubMed
    Score: 0.002
  256. Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1216-24.
    View in: PubMed
    Score: 0.002
  257. Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol. 2002 Jun; 178(6):1383-8.
    View in: PubMed
    Score: 0.002
  258. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 01; 20(5):1167-74.
    View in: PubMed
    Score: 0.002
  259. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002 Jan; 123(1):175-83.
    View in: PubMed
    Score: 0.002
  260. Prognostic value of pretreatment bone scans in breast carcinoma. AJR Am J Roentgenol. 1979 Jun; 132(6):877-81.
    View in: PubMed
    Score: 0.002
  261. Diagnosis of thoracic and lumbar disc disease by gas myelography. Wis Med J. 1976 Apr; 75(4):S29-32.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.